The earnings call highlights several promising developments, including increased market potential and positive safety data for XPro, progress in the INKmune program, and regulatory advancements for CORDstrom. However, these are tempered by financial constraints with a limited cash runway and delays in the U.S. IND for CORDstrom. While the company is optimistic about upcoming milestones, financial sustainability remains a concern.

Company Guidance -

Q2 2025

During the first quarter 2025 earnings call for INmune Bio, management provided several key updates and guidance metrics. Dr. RJ Tesi, CEO, highlighted the anticipated topline results from the MINDFuL Phase 2 trial in early Alzheimer's disease, expected in mid-to-late June. The potential market opportunity for their drug XPro has increased, now believed to be applicable to nearly 70% of early Alzheimer's patients, up from 40%, based on biomarkers and ApoE4 status. The safety profile of XPro remains strong, with no adverse events reported in the trial. Financially, INmune Bio reported a net loss of approximately $9.7 million for the quarter, with research and development expenses at $7.6 million. The company had cash and equivalents of $19.3 million as of March 31, 2025, and expects this to fund operations through the third quarter of 2025. Additionally, the INKmune program in prostate cancer and the CORDstrom program for RDEB are progressing, with plans for a BLA filing for CORDstrom in 2026.

Increased Market Opportunity for XPro in Alzheimer's

Based on recent data, the market opportunity for XPro in early Alzheimer's disease patients has increased to nearly 70% from the previously estimated 40%, due to more patients being eligible based on ApoE4 status.

Positive Safety Profile of XPro

XPro has shown a positive safety profile in the MINDFuL trial, with no reports of adverse events or deaths, making it a safe option for the elderly patient population with Alzheimer's.

Progress in INKmune Program

INKmune has completed Phase 1 dose escalation cohorts with no adverse events, and Phase 2 is underway with promising early results in prostate cancer patients, showing some tumor lesion resolution.

Advancement in CORDstrom Development

CORDstrom is progressing towards a BLA filing in 2026 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), supported by positive trial results and FDA's rare pediatric disease and orphan drug status.

Inmune Bio (INMB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

INMB Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 30, 2025	2025 (Q2)	-0.38 / -	-0.5	―	―	―
May 08, 2025	2025 (Q1)	-0.47 / -0.43	-0.61	29.51% (+0.18)	―
Mar 27, 2025	2024 (Q4)	-0.55 / -0.40	-0.47	14.89% (+0.07)	―
Oct 31, 2024	2024 (Q3)	-0.51 / -0.60	-0.48	-25.00% (-0.12)	―
Aug 01, 2024	2024 (Q2)	-0.63 / -0.50	-0.36	-38.89% (-0.14)	―
May 09, 2024	2024 (Q1)	-0.54 / -0.61	-0.36	-69.44% (-0.25)	―
Mar 28, 2024	2023 (Q4)	-0.43 / -0.47	-0.32	-46.87% (-0.15)	―
Nov 01, 2023	2023 (Q3)	-0.39 / -0.48	-0.43	-11.63% (-0.05)	―
Aug 07, 2023	2023 (Q2)	-0.40 / -0.36	-0.38	5.26% (+0.02)	―
May 03, 2023	2023 (Q1)	-0.02 / -0.36	-0.39	7.69% (+0.03)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

INMB Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 08, 2025	$7.09	$6.97	-1.69%
Mar 27, 2025	$7.41	$7.52	+1.48%
Oct 31, 2024	$5.85	$6.04	+3.25%
Aug 01, 2024	$7.91	$8.17	+3.29%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Inmune Bio Inc (INMB) report earnings?

Inmune Bio Inc (INMB) is schdueled to report earning on Jul 30, 2025, TBA (Confirmed).

What is Inmune Bio Inc (INMB) earnings time?

Inmune Bio Inc (INMB) earnings time is at Jul 30, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is INMB EPS forecast?

INMB EPS forecast for the fiscal quarter 2025 (Q2) is -0.38.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing